The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-Synuclein Therapeutics, 2010Neuroprotective efficacy of RAB3B in pre-clinical models of alpha-synucleinopathy
Objective/Rationale:
In Parkinson’s disease, the major motor symptoms are caused by the degeneration of dopamine producing neurons in the substantia nigra pars compacta. We have identified a... -
Alpha-Synuclein Therapeutics, 2010Testing of Davunetide for Intranasal Administration in Pre-clinical Models Over Expressing Alpha-synuclein
Objective/Rationale:
Davunetide is an investigational drug with the potential to treat Parkinson disease and is currently in a clinical trial for progressive supranuclear palsy, a rare progressive... -
Research Grant, 2010LRRK2 Effects on Neural Differentiation
Objective/Rationale:
Several lines of research suggest that leucine-rich repeat kinase 2 (LRRK2 or PARK8) levels or its activity can regulate the development of axons or dendrites, but some of the... -
MJFF Research Grant, 2010Determine the Structure of LRRK2 Protein
Objective/Rationale:
Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene are associated with Parkinson’s disease (PD). Although the biological function of LRRK2 is not known, inhibitors of... -
MJFF Research Grant, 2010Role of mGluR4 in the Modulation of Levodopa-induced Motor Performance and Dyskinesia
Objective/Rationale:
Dyskinesias are uncontrollable involuntary body movements that constitute a major clinical problem associated with the long term treatment of Parkinson’s disease (PD) using... -
MJFF Research Grant, 2010Developing Circuit-Targeting Optogenetic Strategies for Pre-Clinical Model Motor Circuitry
Objective/Rationale:
Optogenetics is a new technology that allows control of brain cells with light- in a way that allows targeting of control to well-defined subsets of cells in vivo, even if those...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.